Melanoma: Latest Research

Approved by the Cancer.Net Editorial Board, 06/2017

ON THIS PAGE: You will read about the scientific research being done now to learn more about this type of cancer and how to treat it. Use the menu to see other pages.

Doctors are working to learn more about melanoma, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. This section is not meant to be a complete list of new clinical trials because this field is changing rapidly. Always talk with your doctor about the best diagnostic and treatment options for you.

  • Enhanced prevention and early detection methods. There is ongoing research on better prevention and early detection strategies for melanoma. Both primary and secondary prevention are important. Primary prevention involves keeping melanoma from developing, such as reducing exposure of ultraviolet (UV) radiation from the sun and avoiding the use of indoor tanning devices. Secondary prevention includes methods of early detection. One promising area is the screening of people with a high risk of developing melanoma.

  • Targeted therapy. As discussed in Treatment Options, targeted therapy is a treatment that targets specific genes or proteins. Ongoing research has identified a number of molecular pathways and activated or mutated genes in melanoma. Clinical trials are testing new drugs to inhibit the MAP kinase pathway and other pathways that melanoma might use to grow and spread. Strategies to prevent the melanoma from becoming resistant to treatment are also being tested, such as using combinations of drugs or exploring new schedules of giving drugs to patients.

  • Immunotherapy. Researchers are studying new checkpoint inhibitors and immunotherapies directed at other parts of the immune system. These include TIM3 inhibitors, LAG3 inhibitors, OX40 agonists, CD137 agonists, GITR agonists, and IDO inhibitors. Also, a number of combinations of immunotherapies are being looked at, including all of the above agents with anti-PD-1 or anti-PD-L1 antibodies, as well as combinations of targeted therapies with anti-PD-1 or anti-PD-L1 antibodies.

  • Chimeric antigen receptor T-cell (CAR-T) therapy and T-cell receptor (TCR) therapy. Another type of experimental immunotherapy involves altering a person’s white blood cells, known as lymphocytes, in a laboratory. This is done to increase their ability to fight the tumor. The changed cells are given back to the patient, often in combination with chemotherapy, interleukin-2, and/or other immunotherapies.

  • Vaccines. Therapeutic vaccines that may improve the specific immune response to melanoma have been the focus of multiple clinical trials. Melanoma peptide vaccines are being evaluated in clinical trials for patients with both localized and advanced melanoma. Research has shown that vaccination can cause the immune system to fight melanoma, even in advanced disease, but these therapies are still considered experimental. The vaccines are made using certain proteins found only on a melanoma tumor and are given as an injection. The person’s immune system then recognizes the proteins and destroys melanoma cancer cells. To date, no vaccines have shown a clinical benefit in patients. Learn more about cancer vaccines.

  • Palliative care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current melanoma treatments to improve patients’ comfort and quality of life.

Looking for More About the Latest Research?

If you would like additional information about the latest areas of research regarding melanoma, explore these related items that take you outside of this guide:

The next section in this guide is Coping with Treatment. It offers some guidance in how to cope with the physical, emotional, and social changes that cancer and its treatment can bring. You may use the menu to choose a different section to read in this guide.